In some cases, biopsies were taken many years before the participant entered the FAKTION trial, but the original tumour PIK3CA, AKT1, and PTEN status appeared to define the efficacy of capivasertib for advanced breast cancer. The gene discussed is PTEN; the disease is breast cancer.